

Development of tumor ECM-modifying bispecific antibody for cancer immunotherapy

POSTECH



ONCOLOGY	Hit
Product Type	Bispecific antibody
Indication	Breast cancer & Lung cancer
Target	DDR1 and TGF-β
MoA(Mechanism of Action)	Inhibition of collagen matrix formation and TGF-β inactivation with TGF-β receptor II extracellular domain
Competitiveness	<ul style="list-style-type: none"> • Unlike existing DDR1 protein-targeted treatments, the main mechanism is to inhibit changes in collagen fiber structure through an antibody-based form. • Bispecific antibody can inhibit the activation of cancer-associated fibroblasts (CAFs) while promoting the activity of surrounding T cells. • Due to the elevated presence of DDR1 in the microenvironment of cancer cells and tumor stroma compared to normal tissue, the side effects arising from TGF-β small molecule inhibitors can be reduced.
Development Stage	Hit
Route of Administration	Subcutaneous & Intravenous injection